Denosumab Usage Profile Study
Denosumab (common trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, and giant cell tumor of bone.Denosumab is a RANKL inhibitor, which works by preventing the development of osteoclasts.The use of Denosumab has seen extensive application in definitive and adjunctive roles in the musculoskeletal oncology  arena. There have however been no good trials on recommended duration of therapy and dosage in the given situations posed for treatment. It is timely that the APMSTS provides a position statement and I thank you for your valuable contribution to this survey. This should not take more than 5 minutes of your valuable time. It is an independent undertaking by the APMSTS and is not aligned with any commercial entity.

Saminathan Suresh Nathan
President 2014-2016
Asia Pacific Musculoskeletal Tumor Society

Sign in to Google to save your progress. Learn more
Country of practice *
Institution *
Kindly submit only one entry per practitioner. Two practitioners in the same institution can submit 2 entries but there should be no duplication
Email address *
Initials of principal specialist *
eg. DL for David Low
What is your level of use? *
Denosumab preparations used in your practice *
Do you use other anti-osteoclastic therapies *
Non-denosumab anti-osteoclast therapies used in practice *
What conditions do you use denosumab for? *
(Note: In the course of this survey you may return back to this question and choose more than one option. Your answers are captured at each turn)
Clear form
Never submit passwords through Google Forms.
This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy